Precigen announces positive phase 1 dose escalation and expansion cohort data for investigational off-the-shelf prgn-2012 adenoverse™ immunotherapy in patients with recurrent respiratory papillomatosis

–  repeated administrations of prgn-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than grade 2 – –  clinical data show strong response in rrp patients with 50% of patients in complete response, requiring no post-treatment surgeries, following prgn-2012 treatment at dose level 2; all complete responders remain surgery-free post-treatment with a minimum follow up of 12 months – –  prgn-2012 treatment at dose level 2 significantly reduced the need for surgeries in severe, aggressive rrp patients; median number of rrp surgeries in 12-month period reduced from 6.5 pre-treatment to 0.5 post-treatment – –  phase 2 study is enrolling patients with a total of 32 patients enrolled at dose level 2 to date – –  company to outline regulatory strategy in rrp as us food and drug administration ( fda) discussions advance – –  precigen to host r&d day virtual event today at 4:30 pm et – germantown, md. , jan. 24, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announces positive phase 1 dose escalation and expansion cohort data as of the january 12, 2023 cutoff for the investigational, potential first-in-class prgn-2012 off-the-shelf (ots) adenoverse™ immunotherapy in patients with recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking